Episode

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Podcast: BioSpace
Published: Jul 8, 2026
Duration seconds: 1024
Processing state: not_requested
Canonical source: https://api.riverside.com/hosting-analytics/media/296dbeabb7a5553c79e61442d4a88f512b65663f9d12071c7efc2033f8b4bd77/eyJlcGlzb2RlSWQiOiJlNmM5N2FhZi1iN2QyLTQzNTgtOGQ2NC02YTRjZTBjY2JlZmQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0ZDQ4MjllMThiYTBmOTljZDljNWFlL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTdfXzIwLTQwLTQxLm1wMyJ9.mp3
Audio: https://api.riverside.com/hosting-analytics/media/296dbeabb7a5553c79e61442d4a88f512b65663f9d12071c7efc2033f8b4bd77/eyJlcGlzb2RlSWQiOiJlNmM5N2FhZi1iN2QyLTQzNTgtOGQ2NC02YTRjZTBjY2JlZmQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0ZDQ4MjllMThiYTBmOTljZDljNWFlL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTdfXzIwLTQwLTQxLm1wMyJ9.mp3
JSON: /v1/public/podcasts/biospace-6696251/episodes/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil
Markdown: /podcast/biospace-6696251/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil.md

Actions

POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/biospace-6696251/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.